Introduction {#S1}
============

Noroviruses (NoVs) are a major cause of acute epidemic viral gastroenteritis worldwide ([@B19]; [@B50]). In developing countries, 200,000 deaths in children less than 5 years of age are estimated to be caused by NoV infections ([@B46]). Large-scale foodborne illnesses have been caused worldwide by NoVs ([@B32]; [@B49]; [@B23]; [@B51]). It is estimated that NoVs are responsible for 699 million gastroenteritis cases per year, costing approximately \$60 billion in medical and socioeconomic costs ([@B3]). Thus, NoV infection is a serious disease burden in many countries ([@B34]; [@B30]; [@B22]).

NoV belongs to the family *Caliciviridae*, genus *Norovirus*, and is classified into 10 genogroups (GI-GX) ([@B12]). The GI, GII, GIV, GVIII and GIX genogroups of NoV can infect humans ([@B12]). GI and GII viruses are frequently detected in humans, and are further classified into 9 and 27 genotypes, respectively, based on the capsid region sequences ([@B12]). Previous molecular epidemiological studies have shown that some NoV GII genotypes, including GII.2, GII.3, GII.4, GII.6, and GII.17 are prevalent in different countries ([@B38]; [@B8], [@B9]; [@B10]; [@B59]).

The NoV genome is a positive-sense, single-stranded RNA composed of three open reading frames (ORFs). ORF1 encodes six non-structural proteins including protease (Pro) and RNA-dependent RNA polymerase (RdRp). Pro plays a critical role in proteolytic cleavage of a large polyprotein encoded in the ORF1 ([@B33]; [@B4]). Thus, Pro is one of the essential enzymes in NoV propagation in host cells. Pro could be a major target for antiviral drugs, in addition to RdRp. Many studies have been conducted into the development of drug candidates ([@B24]; [@B42]; [@B43]; [@B57]). A recent report demonstrated different effectiveness of antivirals against GI and GII NoVs, suggesting that the amino acid diversity in Pro may result in different effectiveness of drugs ([@B57]). It is important to understand the evolution of the *Pro* region of GII NoV, because this virus is the predominant genogroup in patients with NoV infection. However, to the best of our knowledge, there are no reports related to a comprehensive molecular evolutionary analysis of the GII *Pro* region. We conducted a detailed evolutionary analysis of the NoV GII *Pro* region using large numbers of strains, and using the latest bioinformatics approaches.

Materials and Methods {#S2}
=====================

Strain Selection {#S2.SS1}
----------------

Full-length nucleotide sequences (543 nt) of the NoV GII *Pro* region were collected from GenBank^[1](#footnote1){ref-type="fn"}^ (accessed on 17 November 2018). We classified these strains according to ORF1 using a norovirus genotyping tool ([@B29]) and selected all the sequences of the human NoV (HuNoV) GII. Strains with an unknown collection year and ambiguous sequences with undetermined nucleotides (such as N, Y, and V) were omitted from the dataset. After these eliminations, the dataset consisted of the *Pro* region sequences of approximately 1,500 strains. However, because of the limitations in the software's capacity, it could not be used for the detection of recombination. Thus, we calculated the nucleotide identity among the 1,500 *Pro* region sequences using Clustal Omega ([@B53]). We randomly selected one sequence from a group of homologous sequences with identity ≥99.8% and excluded the others from the dataset to reduce the sequences in the dataset. Furthermore, to estimate the recombination of the *Pro* region in the present strains, recombination analyses were performed using the RDP4.95 software with seven primary exploratory recombination signal detection methods: RDP, GENECONV, BOOTSCAN/RESCAN, MAXCHI, CHIMAERA, SISCAN, and 3SEQ ([@B37]). The threshold of the *p*-value for significance was set to 0.001. Recombinant regions were considered to be reliable when they were detected by more than four of these methods; however, no recombinant strains in the present sequences were estimated. Finally, a total of 760 strains were used in this study ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The sequences in the dataset were aligned using the MAFFT software ([@B27]).

Construction of a Time-Scaled Phylogenetic Tree Using the Bayesian Markov Chain Monte Carlo Method {#S2.SS2}
--------------------------------------------------------------------------------------------------

We constructed a time-scaled phylogenetic tree using the Bayesian MCMC method in the BEAST software package v2.4.8 ([@B17]; [@B6]). To estimate the phylogenetic relationships in the *Pro* region between distinct NoVs genogroups, we added the nucleotide sequences of human NoV GI (GI.P1), porcine GII (GII.P11 and GII.P18), bovine GIII (GIII.P1) and human GIV (GIV.P1) strains to the dataset, giving a total of 765 strains. We determined the best substitution model (GTR+I+Γ) using the jModelTest2 software ([@B21]; [@B14]). We then selected the best of four clock models -- strict clock, relaxed clock exponential, relaxed clock log normal or random local clock -- and two tree prior models, coalescent constant population and coalescent exponential population, using path sampling/stepping stone-sampling marginal-likelihood estimation ([@B1]). The dataset was analyzed using strict clock and tree prior of coalescent exponential population. The MCMC was run on chain lengths of 150,000,000 steps with sampling every 5,000 steps. The data were then evaluated for effective sample size using the Tracer^2^ software, and values greater than 200 were accepted. Maximum clade credibility trees were created by discarding the first 10% of the trees (burn-in) using TreeAnnotator v2.4.8 in the BEAST2 package. The time-scaled phylogenetic trees were visualized using FigTree^[3](#footnote3){ref-type="fn"}^ v1.4.0 software. The reliability of branches was assessed using the 95% highest posterior density (HPD) interval. The evolutionary rates for the *Pro* region in the ORF1 genotypes of NoV GII including more than 10 strain sequences (P4, P7, P12, P16, P17, P21, and P31) were also estimated using the models determined from the datasets described above. We could not calculate the evolutionary rate for the *Pro* region of GII.P2 due to invalid data with a wide range of 95%HPD values.

Calculation of Phylogenetic Distances {#S2.SS3}
-------------------------------------

We created phylogenetic trees for the *Pro* region from the datasets of the NoV GII strains and each ORF1 genotype including more than 10 strains using the maximum likelihood (ML) method in the MEGA7 software package ([@B31]). We determined the best substitution models using jModelTest2. We calculated the phylogenetic distances between NoV GII strains from the ML distance of the ML tree using the Patristic software ([@B18]).

Construction of Three-Dimensional Structures and Selective Pressure Analyses {#S2.SS4}
----------------------------------------------------------------------------

We constructed structural models of the Pro proteins (GII.P1:U07611, GII.P2:DQ456824, GII.P3:KJ194500, GII.P4:AB 541272, GII.P5:KJ196288, GII.P6:AB039778, GII.P7:AB039777, GII.P8:AB039780, GII.P12:AB220922, GII.P16:KJ196286, GII. P17:AB983218, GII.P20:EU424333, GII.P21:KJ196284, GII.P24: MG495081, GII.P25:MG495083, GII.P30:AY134748, GII.P31: JX459907, GII.P32:MF405169, GII.P33:GQ845370, GII.P35:KC 576911, GII.P37:KJ194507, GII.P39:FJ537134, GII.P40:DQ3 66347, GII.P41:JX846924, GII.PNA5:MG495082, and GII.PNA7: MG557653) using the homology modeling software, MODELER v9.20 ([@B60], [@B61]). The crystal structure of the GII.P4 Pro protein (PDB ID: 6NIR) was used as the template for homology modeling. Amino acid sequences of the template and targets were aligned using the MAFFTash software ([@B54]; [@B26]). The constructed structures were minimized using GROMOS96 ([@B56]) implemented in Swiss PDB Viewer v4.1 ([@B20]), and structural reliability was evaluated using Ramachandran plots via the RAMPAGE server ([@B35]). We identified favored regions of 97.49 ± 0.52%, allowed regions of 2.50 ± 0.51% and outlier regions of 0.01 ± 0.06% \[mean ± standard deviation (SD)\] of all residues in each structure. Non-synonymous (dN) and synonymous (dS) substitution rates at each codon were calculated to estimate the positive and negative selection sites in the NoV GII *Pro* regions and in the regions of each genotype including more than three strains using the Datamonkey server ([@B48]; [@B15]). We identified the consensus sites shown by three methods: single-likelihood ancestor counting (SLAC), fixed effects likelihood (FEL), and internal fixed effects likelihood (IFEL) using a significance level of *p* \< 0.05. We assigned these consensus sites as sites under positive, negative or neutral selection. A two-tail extended binomial distribution was used to calculate the *p*-value for SLAC. The FEL and IFEL were based on a single degree of freedom likelihood ratio test using an asymptotic chi-squared distribution, in order to classify a site as positively or negatively selected. The final structural models were modified and colored using the Chimera v1.13 software ([@B47]). The substitution sites of the other Pro proteins were compared to a GII.P20 strain (accession no. [EU424333](EU424333)) and negative selection at these sites was mapped onto the structure.

Bayesian Skyline Plot Analysis {#S2.SS5}
------------------------------

We estimated the genealogical population size of the *Pro* region in the ORF1 genotypes of NoV GII including \>10 strain sequences (P2, P4, P7, P12, P16, P17, P21, and P31) using a Bayesian skyline plot algorithm using BEAST v2.4.8. Appropriate substitution and clock models were selected as described above. The plots were visualized with 95%HPD using Tracer^[2](#footnote2){ref-type="fn"}^.

Statistical Analyses {#S2.SS6}
--------------------

Statistical analyses were conducted using the EZR statistical software implementation of the Kruskal--Wallis test controlled for multiple comparisons using the Holm test for phylogenetic distances ([@B25]). Detailed statistical data are presented in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}.

Results {#S3}
=======

Time-Scaled Phylogenetic Tree Constructed Using the Bayesian MCMC Method {#S3.SS1}
------------------------------------------------------------------------

We constructed a time-scaled phylogenetic tree of the *Pro* region of NoV GII using a Bayesian MCMC method. The 26 ORF1 genotypes of the HuNoV GII strains were classified into three lineages by setting the cut-off value of phylogenetic distances for lineages as 0.9 substitutions/site ([Figures 1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}). With this threshold, we obtained lineage 1 (GII.P6-P8 and P20); lineage 2 (GII.P1-P5, P12, P16, P17, P21, P30--P33, P35, P37, P39, P41, and PNA7) and lineage 3 (GII.P24, P25, P40, and PNA5) ([Figure 1](#F1){ref-type="fig"}). Strains with the GII.P4 formed many clusters of short duration.

![Time-scaled phylogenetic tree of full-length NoV *Pro* regions constructed using a Bayesian MCMC method. The maximum clade credibility tree of a dataset including the NoV GI, GII, GIII, and GIV genogroups is shown. Blue bars indicate the 95% HPD for each divergent year.](fmicb-10-02991-g001){#F1}

The phylogenetic tree indicated that GI diverged from the common ancestor of GII, GIII, and GIV in 1143 CE (95%HPD, 895--1370), and GIII diverged from the common ancestor of GII and GIV in 1250 CE (95%HPD, 1031--1447). The common ancestor of GII diverged from GIV in 1680 CE (95%HPD, 1607--1749). The common ancestor of NoV GII viruses formed three lineages after 1752 CE (95%HPD, 1707--1794). Lineage 1 diverged in 1873 CE (95%HPD, 1847--1898), lineage 2 in 1868 CE (95%HPD, 1844--1892) and lineage 3 in 1966 CE (95%HPD, 1956--1977). We show the estimated divergence year for the three lineages, and the ORF1 genotypes including two or more strains in [Table 1](#T1){ref-type="table"}. GII.P20 diverged first from a common ancestor with the other HuNoV GII in 1873 CE (95%HPD, 1847--1898; [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}).

###### 

Year of divergence of each ORF1 genotype for HuNoV GII.

  **Genogroup**   **Lineage**   **ORF1 genotypes**                                                     **Year of divergence (95% HPD)**
  --------------- ------------- ---------------------------------------------------------------------- ----------------------------------
  GII             1             GII.P6-P8 and P20                                                      1873 (1847--1898)
                  2             GII.P1-P5, P12, P16, P17, P21, P30-P33, P35, P37, P39, P41, and PNA7   1868 (1844--1892)
                  3             GII.P24, P25, P40, and PNA5                                            1966 (1956--1977)
                                GII.P2                                                                 2001 (1999--2003)
                                GII.P3                                                                 1993 (1992--1995)
                                GII.P4                                                                 1981 (1979--1983)
                                GII.P6                                                                 1961 (1956--1965)
                                GII.P7                                                                 1981 (1978--1984)
                                GII.P8                                                                 1983 (1979--1986)
                                GII.P12                                                                1992 (1988--1995)
                                GII.P16                                                                1992 (1988--1996)
                                GII.P17                                                                2011 (2010--2012)
                                GII.P21                                                                1998 (1995--2002)
                                GII.P24                                                                2012 (2011--2013)
                                GII.P30                                                                1970 (1967--1972)
                                GII.P31                                                                2001 (1999--2004)
                                GII.P33                                                                2003 (2000--2005)
                                GII.P39                                                                1969 (1967--1972)
                                GII.P40                                                                2000 (1998--2001)
                                GII.P41                                                                1964 (1960--1968)

HPD, highest posterior density.

We also estimated the evolutionary rates for the *Pro* region in HuNoV GII strains and each ORF1 genotype ([Figure 2](#F2){ref-type="fig"}). The evolutionary rate of this region in the HuNoV GII strains (760 strains) was estimated as 3.94 × 10^--3^ substitutions/site/year (95% HPD, 3.16--4.70 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P4 was 4.41 × 10^--3^ substitutions/site/year (95% HPD, 3.71--5.12 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P7 was 3.90 × 10^--3^ substitutions/site/year (95% HPD, 2.91--4.95 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P12 was 3.85 × 10^--3^ substitutions/site/year (95% HPD, 2.45--5.31 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P16 was 4.15 × 10^--3^ substitutions/site/year (95% HPD, 3.17--5.14 × 10^--3^ substitutions/site/year. The evolutionary rate of GII.P17 was 1.89 × 10^--3^ substitutions/site/year (95% HPD, 4.99 × 10^--4^--3.43 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P21 was 5.27 × 10^--3^ substitutions/site/year (95% HPD, 3.18--7.51 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P31 was 4.09 × 10^--3^ substitutions/site/year (95% HPD, 2.32--6.04 × 10^--3^ substitutions/site/year). The average evolutionary rates, including 95%HPD ranges, showed no overlap between GII.P17 and GII.P4, which suggests different evolutionary rates.

![Evolutionary rates of the full-length nucleotide sequences of the NoV *Pro* regions. The *y-*axis represents the evolutionary rate (substitutions/site/year) and the *x*-axis indicates each genotype. The black circles indicate the mean and the bars indicate the interval of 95% HPD. The evolutionary rate of this region in overall HuNoV GII strains (760 strains) was estimated as 3.94 × 10^--3^ substitutions/site/year (95% HPD, 3.16--4.70 × 10^--3^ substitutions/site/year). The evolutionary rates of GII.P4 was 4.41 × 10^--3^ substitutions/site/year (95% HPD, 3.71--5.12 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P7 was 3.90 × 10^--3^ substitutions/site/year (95% HPD, 2.91--4.95 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P12 was 3.85 × 10^--3^ substitutions/site/year (95% HPD, 2.45--5.31 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P16 was 4.15 × 10^--3^ substitutions/site/year (95% HPD, 3.17--5.14 × 10^--3^ substitutions/site/year. The evolutionary rate of GII.P17 was 1.89 × 10^--3^ substitutions/site/year (95% HPD, 4.99 × 10^--4^--3.43 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P21 was 5.27 × 10^--3^ substitutions/site/year (95% HPD, 3.18--7.51 × 10^--3^ substitutions/site/year). The evolutionary rate of GII.P31 was 4.09 × 10^--3^ substitutions/site/year (95% HPD, 2.32--6.04 × 10^--3^ substitutions/site/year).](fmicb-10-02991-g002){#F2}

Phylogenetic Distances of the *Pro* Region in Norovirus GII Strains {#S3.SS2}
-------------------------------------------------------------------

We calculated the number of nucleotide substitutions per site (phylogenetic distance) among the strains and showed the distribution of the distance to estimate the genetic diversity of the ORF1 genotypes and to compare the number between the genotypes in the *Pro* region of NoV GII. The average number of substitutions of overall NoV GII was 0.517 ± 0.469 per site in the region (mean ± SD; [Figure 3](#F3){ref-type="fig"}). The phylogenetic distances of GII.P4 and GII.P7 were 0.070 ± 0.041 and 0.113 ± 0.057 substitutions/site, respectively. These histograms were distributed with a broad range of distances, indicating accumulating evolution with viral detection for long periods from the emergence of common ancestors ([Figures 4B,C](#F4){ref-type="fig"}). The phylogenetic distances of GII.P2, GII.P12, GII.P17, GII.P21, and GII.P31 were 0.046 ± 0.017, 0.062 ± 0.025, 0.015 ± 0.009, 0.045 ± 0.026, and 0.031 ± 0.024 substitutions/site, respectively. These histograms were distributions with a narrow range of distances, suggesting shorter evolutionary process from the emergence of common ancestors than GII.P4 and GII.P7 ([Figures 4A,D,F--H](#F4){ref-type="fig"}). The phylogenetic distance of GII.P16 was 0.078 ± 0.069 substitutions/site. This histogram showed a bimodal distribution, indicating the form of genetically distant two clusters ([Figure 4E](#F4){ref-type="fig"}). The phylogenetic distances of each ORF1 genotype differed significantly among the ORF1 genotypes in NoV GII (*p* \< 0.001), except for some ORF1 genotypes. Detailed data are presented in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}.

![Distribution of phylogenetic distances of GII strains. The phylogenetic distance among NoV GII strains was calculated from the maximum likelihood (ML) tree constructed by the ML method. The *y*-axis represents the number of sequence pairs corresponding to each distance, and the *x*-axis shows the phylogenetic distance (substitutions/site). The distribution of phylogenetic distance for≥0.9 substitutions/site is shown in gray. The numbers on the histograms indicate the mean ± SD of the phylogenetic distance for GII strains.](fmicb-10-02991-g003){#F3}

![Phylogenetic distance between sequences of the full-length NoV *Pro* region. The phylogenetic distance between each genotype strain in NoV GII was calculated from the ML tree constructed by the ML method. The distributions of phylogenetic distances of NoV GII.P2 **(A)**, GII.P4 **(B)**, GII.P7 **(C)**, GII.P12 **(D)**, GII.P16 **(E)**, GII.P17 **(F)**, GII.P21 **(G)**, and GII.P31 **(H)** are shown. The *y*-axis represents the number of sequence pairs corresponding to each distance, and the *x*-axis shows the phylogenetic distance (substitutions/site). The numbers on the histograms indicate the mean ± SD of the phylogenetic distances for each genotype **(A--H)**. The statistical results for multiple comparisons are shown in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}.](fmicb-10-02991-g004){#F4}

Mapping of Amino Acid Substitutions and Negative Selection Sites on the Structures of the Norovirus GII Pro Protein {#S3.SS3}
-------------------------------------------------------------------------------------------------------------------

The substitution sites of the other Pro proteins to GII.P20 were mapped using GII.P20 (Accession no. [EU424333](EU424333)) as a reference strain, because GII.P20 was the first to diverge from the common ancestor of the HuNoV GII *Pro* region ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). We found no substitutions on the active site (H30, H54, and C139) of the protease among GII strains. However, some amino acid substitutions were found near the active site of GII Pro proteins. These substitutions were mostly neutral selection sites ([Figure 5](#F5){ref-type="fig"} and [Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). We also mapped the negative selection sites and amino acid substitution sites on the Pro protein structures of NoV GII. Of the substitution sites in each ORF1 genotype, the GII.P4 and GII.P16 strains contained 20 and 6 negative selection sites per monomer, respectively ([Table 2](#T2){ref-type="table"}), and these sites were distant from the active site ([Figure 5](#F5){ref-type="fig"}). There were five or fewer negative selection sites per monomer in some ORF1 genotypes (GII.P7, P12, P21, and P31), while no negative selection sites were found in the GII.P1, P2, P3, P6, P17, P30, P33, P39, P40, and P41 strains ([Table 2](#T2){ref-type="table"}). The consensus amino acid site under negative selection among three ORF1 genotypes was 58Leu (GII.P4, P21, and P31) ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}). The consensus sites between two ORF1 genotypes were 11Ser (GII.P4 and P16), 25Phe (GII.P4 and P16), 47Ile (GII.P4 and P7), 62Lys (GII.P4 and P12), 87Ile (GII.P4 and P7), 129Ser and Gly (GII.P4 and P16), 135Thr and Gly (GII.P4 and P7), 151Tyr (GII.P4 and P16) ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}). These sites under the negative selection were highly conserved, except for 129 and 135 amino acid positions. No positive selection sites were predicted in all strains of NoV GII genotypes (data not shown). The residues of amino acid under neutral selection were 12Phe and Leu, 14Ser and Thr, 25Phe and Leu, 26Ile and Val, 28Ser and Thr, 32Leu and Ile, 34Ala, Lys, Gln, Pro and Ser, 35Gly and Asn ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}).

![Structural models for the Pro protein of each genotype. Three-dimensional Pro dimer structures for GII.P4 **(A)**, GII.P7 **(B)**, GII.P12 **(C)**, GII.P16 **(D)**, GII.P21 **(E)**, and GII.P31 **(F)** are shown. The chains composing the dimer structures are colored gray (chain A) and Navajo white (chain B). Negative selection sites are colored green. Amino acid substitutions of the other genotypes compared to a GII.P20 strain are colored blue. Active site residues are colored red.](fmicb-10-02991-g005){#F5}

###### 

The number of amino acid substitution sites and negative selection sites in the HuNoV GII strains.

  **ORF1 genotypes**   **Number of substitution sites**   **Number of negative selection sites^‡^**
  -------------------- ---------------------------------- -------------------------------------------
  GII.P1               35                                 0 (0%)
  GII.P2               38                                 0 (0%)
  GII.P3               33                                 0 (0%)
  GII.P4               36                                 20 (55.6%)
  GII.P6               8                                  0 (0%)
  GII.P7               7                                  3 (42.9%)
  GII.P12              35                                 1 (2.9%)
  GII.P16              35                                 6 (17.1%)
  GII.P17              32                                 0 (0%)
  GII.P21              35                                 1 (2.9%)
  GII.P30              36                                 0 (0%)
  GII.P31              36                                 1 (2.8%)
  GII.P33              36                                 0 (0.0%)
  GII.P39              35                                 0 (0.0%)
  GII.P40              38                                 0 (0.0%)
  GII.P41              35                                 0 (0.0%)

†

The number of substitution sites per monomer of other Pro proteins compared to the GII.P20 strain are presented.

‡

The number of negative selection sites on the substitution sites. The negative selection sites were identified as the consensus sites shown by the SLAC, FEL, and IFEL methods.

Phylodynamics of the *Pro* Region in the Norovirus GII Strains Using the BSP Method {#S3.SS4}
-----------------------------------------------------------------------------------

The phylodynamics of the NoV GII *Pro* region were analyzed using the BSP method and detailed parameters are shown in [Supplementary Table S4](#SM1){ref-type="supplementary-material"}. The mean effective population size of GII.P4 increased around 2005 and 2008 ([Figure 6B](#F6){ref-type="fig"}). The mean effective population sizes of GII.P7, GII.P16, GII.P21, and GII.P31 increased around 2012, 2015--2016, 2014--2015, and 2011--2012, respectively, while no changes in the population size of the *Pro* region in other ORF1 genotypes were observed ([Figures 6A,C--H](#F6){ref-type="fig"}).

![Bayesian skyline plot for the NoV GII strains. Plots for GII.P2 **(A)**, GII.P4 **(B)**, GII.P7 **(C)**, GII.P12 **(D)**, GII.P16 **(E)**, GII.P17 **(F)**, GII.P21 **(G)**, and GII.P31 **(H)** are shown. The *y*-axis represents the effective population size on a logarithmic scale, while the *x*-axis denotes the time in years. The solid black line indicates the mean posterior value and intervals with 95% HPD are represented by blue lines.](fmicb-10-02991-g006){#F6}

Discussion {#S4}
==========

We studied the molecular evolution of the *Pro* regions in NoV GII. To the best of our knowledge, there is no comprehensive molecular evolutionary study focused on the NoV *Pro* regions. Our findings suggest that (i) the common ancestor of the *Pro* region of the analyzed strains, including GI, GII, GIII, and GIV, diverged around 880 years ago (1143 CE), and the GII *Pro* region diverged from GIV around 340 years ago (1680 CE) and formed three major lineages of NoV GII strains around 270 years ago (1752 CE); (ii) the estimated evolutionary rate of the *Pro* region was \>10^--3^ substitutions/site/year, and the values for each genotype were different; (iii) several amino acid substitutions (7--38 sites per monomer) in the GII protease were detected under neutral selection proximal to the active sites and under negative selection in the distant residues from the sites, and (iv) the phylodynamics of the GII *Pro* region showed different patterns of fluctuation between genotypes. These results suggested that the *Pro* region of the NoV GII evolved rapidly with amino acid substitutions under no positive selection, and the evolutionary trends were different between the ORF1 genotypes.

A time-scaled phylogenetic tree constructed using a Bayesian MCMC method indicated that the *Pro* region showed similar evolutionary process to the *RdRp* region, but was different from the *VP1* region at post emergence of the GII cluster, including the generations of three lineages ([@B28]; [@B45]). We estimated that the *Pro* region, the *RdRp* region and the *VP1* region diverged around 270 years ago (1752 CE), around 290 years ago (1731 CE) and around 390 years ago (1630 CE), respectively, to form the GII cluster. The years of divergence of the *Pro* and *RdRp* regions were very similar (270 vs. 290 years ago), whereas the year of divergence of the *VP1* region was different by approximately 100 years. The year in divergence of each lineage was comparable between the *Pro* and *RdRp* regions ([@B45]). We estimated that in lineage 1 the *Pro* region diverged around 150 years ago (1873 CE) and the *RdRp* region around 170 years ago (1847 CE). In lineage 2, the *Pro* and the *RdRp* regions diverged around 150 years ago (1868 CE). In lineage 3, the *Pro* region diverged around 50 years ago (1966 CE) and the *RdRp* region around 80 years ago (1936 CE). [@B45] recently classified 23 ORF1 genotypes in the HuNoV GII strains into three lineages: lineage 1 (GII.P6-P8, P15 and P20), lineage 2 (GII.P1-P5, P12, P16, P17, P21, P30-P33, P35, and P37), and lineage 3 (GII.P22, P23, and P24). The phylogenetic topology in the ORF1 genotypes and the year of divergence of each lineage were almost analogous between the *Pro* and the *RdRp* regions. Thus, we estimated that the *Pro* and *RdRp* regions undergo shared evolution without recombination in NoV GII. However, we found incompatibility between the topology and the divergent year between the *Pro* and the *VP1* regions ([@B28]), suggesting distinct evolutionary patterns with recombination between the *Pro/RdRp* region and the *VP1* region in NoV GII.

Several evolutionary studies of the *VP1* region and the *RdRp* region of NoVs have been carried out ([@B5]; [@B52]; [@B36]; [@B28]; [@B41]). In a study of NoV protease, [@B13] estimated the evolutionary rate of the 3CL-Pro in GII.P4-GII.4 as 6.03 × 10^--3^ substitutions/site/year. However, there appears to be no comprehensive evolutionary studies using strains collected globally. This study showed that the evolutionary rate of the GII *Pro* region was estimated at 3.94 × 10^--3^ substitutions/site/year, and that evolution at different rates occurred between the ORF1 genotypes ([Figure 2](#F2){ref-type="fig"}). The *Pro* region evolved rapidly (\>10^--3^ substitutions/site/year) as did the *VP1* region and the *RdRp* region ([@B28]; [@B45]). We therefore speculate that evolutionary rates in the other regions on the NoV genome were rapid.

We analyzed the phylogenetic distances among strains of each genotype, and discovered that the distances differed among strains for each genotype ([Figures 4A--H](#F4){ref-type="fig"}). The histograms of the distances of the GII.P4 and GII.P7 indicated a broad range of distributions, suggesting that they are more genetically diverse than the other ORF1 genotypes. The histograms of the distances of GII.P2, GII.P12, GII.P17, GII.P21, and GII.P31 showed a narrow range distribution, suggesting low genetic divergence. The histogram of the distance of GII.P16 showed a bimodal distribution, suggesting that they contain two distinct groups within the same genotype. The trends of phylogenetic distance distribution among genotypes in the GII *Pro* region were analogous to that of the GII *RdRp* region ([@B45]). Thus, it appears that the GII *Pro* and *RdRp* regions might co-evolve.

We also predicted negative selection sites in the Pro protein *in silico*, and mapped these sites ([Figure 5](#F5){ref-type="fig"}). We identified several possible negative selection sites in the Pro proteins of each genotype. Of them, the GII.P4 Pro protein contained more negative selection sites (20 sites per monomer) at the amino acid substitution sites than other genotypes. The substitution sites under negative selection were separated from the active site of NoV GII protease ([Figure 5](#F5){ref-type="fig"}). In general, negative selection could be important in preventing the loss of viral protein function, because a high proportion of mutations will be deleterious ([@B16]). These results may suggest that the amino acid substitutions distant from the active site in the GII Pro proteins are deleterious for viral propagation, probably, due to instability of the protein structure. We also found that relatively many amino acid substitutions occurred near the active site of the GII Pro proteins ([Figure 5](#F5){ref-type="fig"}, [Supplementary Table S3](#SM1){ref-type="supplementary-material"} and [Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). These substitutions were mostly predicted to be under neutral selection. Thus, the substitutions may not influence the loss of the GII Pro protein function but may change the cleavage activity and affect the efficiency of viral propagation. A previous study reported that the amino acids adjacent to the active sites in the Pro protein of enterovirus 71 play a crucial role in protease activity based on the reduction of activity caused by the mutations of the residues ([@B58]). Moreover, [@B57] reported that the NoV GII protease showed activity in a pH-dependent manner by interactions between the residues H30 and R112. In this study, we found that these amino acids were conserved in most GII genotypes, except for GII.P25 ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}). Therefore, these results suggest that the GII genotypes have a potential to exhibit pH-dependent protease activity.

The phylodynamics of each ORF1 genotype were also assessed in this study ([Figure 6](#F6){ref-type="fig"}). The phylodyamics of GII.P4, GII.P7, GII.P16, GII.P21, and GII.P31 fluctuated at specific times. GII.P4 increased around 2005 and 2008. GII.P7, GII.P16, GII.P21, and GII.P31 increased around 2012, 2015--2016, 2014--2015, and 2011--2012, respectively. In GII.P4 and GII.P31, the collection year of GII.4 agreed with the year when the population size increased. In GII.P7 and GII.P21, the collection year of GII.6 and GII.3, respectively, was almost consistent with the year in which the population size increased. In GII.P16, the collection year of GII.2 and GII.4 corresponded with the year of increase of population size ([@B44]; [@B2]). Previous reports have shown a correlation between fluctuations in population size and the epidemiology of actual outbreaks ([@B39], [@B40]; [@B11]; [@B55]; [@B44]; [@B2]; [@B7]). In this study, we observed similar results in the phylodynamics of NoV protease according to the *VP1* and *RdRp* regions ([@B28]; [@B45]). These results suggest that it is useful to analyze phylodynamics focused on the *Pro* region in order to investigate past epidemics of each NoV genotype. This study has a limitation, in that it used a restricted number of GII *Pro* sequences from the GenBank. In addition, sequences with ≥99.8% identity were omitted. These selection biases may have affected the results of the bioinformatics analyses to some extent.

Conclusion {#S5}
==========

In conclusion, we estimated that the common ancestor of the GII *Pro* region diverged many years ago, and NoV GII evolved rapidly. The GII *Pro* regions and proteins evolved with many amino acid substitutions, but no positively selective pressure was identified. The substitutions under neutral selection adjacent to the active sites of the proteins suggest that the GII genotypes have a potential to alter the protease activity. This study indicates a need to compare the efficiency of antiviral drugs for the Pro protein between NoV genotypes in conjunction with continuing investigation into the evolution of the NoV *Pro* region and the activity of the protein *in vitro*.
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